trending Market Intelligence /marketintelligence/en/news-insights/trending/dnebldpyg99lhysxyqjksg2 content esgSubNav
In This List

UK approves Novartis CAR-T therapy for children with blood cancer

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


UK approves Novartis CAR-T therapy for children with blood cancer

The U.K. National Health Service reached a commercial deal with Novartis AG to make the Swiss drugmaker's personalized chimeric antigen receptor T cell therapy Kymriah available to children and young people with a type of blood cancer.

SNL Image

Kymriah, also known as tisagenlecleucel, costs about £282,000 per patient at its full list price and is licensed to treat patients up to 25 years of age suffering from B cell acute lymphoblastic leukemia that has returned after treatment.

The therapy is designed to reprogram a patient's own immune system cells, which are then used to target their cancer.

The drug recently received approval in the EU to treat blood cancer.

The NHS approval comes a week after health authorities in England rejected a similar treatment by Gilead Sciences Inc. called Yescarta.